Propanc Biopharma, Inc.
PPCB
$1.86
-$0.09-4.62%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 33,280.25% | -30.60% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 24,796.30% | -26.62% | |||
| Operating Income | -24,796.30% | 26.62% | |||
| Income Before Tax | -12,467.95% | -21.42% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -12,467.95% | -21.42% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -12,467.95% | -21.42% | |||
| EBIT | -24,796.30% | 26.62% | |||
| EBITDA | -24,807.92% | 26.63% | |||
| EPS Basic | 61.22% | -- | |||
| Normalized Basic EPS | 60.06% | -- | |||
| EPS Diluted | 61.22% | -- | |||
| Normalized Diluted EPS | 60.06% | -- | |||
| Average Basic Shares Outstanding | 32,426.32% | -- | |||
| Average Diluted Shares Outstanding | 32,426.32% | -- | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||